Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
On May 6, 2020, Novartis announced today that the U.S. Food and Drug Administration (FDA) has approved Tepotinib™ (Capmatinib, formerly known as INC280), an oral MET inhibitor, for···【more】
Article source：Captain MedicineRelease date：2026-01-09Recommended：146
Trametinib (Mekinist) is a targeted therapy indicated for the treatment of unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations. As a prescription-only medic···【more】
Article source：Captain MedicineRelease date：2026-01-08Recommended：139
Ixazomib is a proteasome inhibitor, and its mechanism of action helps kill cancer cells.Which drugs interact with Ixazomib?Concurrent use of this product with any of the following ···【more】
Article source：Captain MedicineRelease date：2026-01-08Recommended：166
Ixazomib Citrate is approved for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior lin···【more】
Article source：Captain MedicineRelease date：2026-01-08Recommended：137
Ixazomib has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory multiple myeloma.Precautions for the Administration of Ixazomi···【more】
Article source：Captain MedicineRelease date：2026-01-08Recommended：173
Ixazomib is available in capsule dosage form and is a prescription-only medicine, which must be purchased with a doctor’s prescription.Precautions for IxazomibDuring treatment with···【more】
Article source：Captain MedicineRelease date：2026-01-08Recommended：171
Ixazomib is classified as an antineoplastic agent (anticancer drug). Its mechanism of action involves interfering with the growth of cancer cells and ultimately enabling the body t···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：138
Ixazomib, in combination with lenalidomide and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least one prior line of therapy.···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：131
Ixazomib is a proteasome inhibitor drug. Its mechanism of action is to prevent multiple myeloma cells from breaking down proteins, leading to the accumulation of intracellular prot···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：145
Ixazomib is typically indicated for the treatment of multiple myeloma, a type of blood cancer. On the basis of a physician’s clinical judgment, ixazomib may also be used for other ···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：151
Ixazomib is indicated for the treatment of multiple myeloma. Its mechanism of action involves blocking a protein that promotes the growth and proliferation of cancer cells, thereby···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：160
Ixazomib is a medication indicated for the treatment of multiple myeloma, exerting its therapeutic effect by inhibiting the growth of cancer cells. This malignancy may affect the b···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：150
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：4512025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：6382024-09-07
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended：952026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：4162025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：4402025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：4252025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：4802025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3882025-01-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
